Novo Nordisk A/S (NYSE:NVO) Holdings Lifted by Whittier Trust Co.

Whittier Trust Co. increased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 29.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,186 shares of the company’s stock after buying an additional 13,390 shares during the quarter. Whittier Trust Co.’s holdings in Novo Nordisk A/S were worth $5,091,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Fifth Third Wealth Advisors LLC boosted its position in Novo Nordisk A/S by 104.9% during the third quarter. Fifth Third Wealth Advisors LLC now owns 3,659 shares of the company’s stock valued at $436,000 after purchasing an additional 1,873 shares during the last quarter. Prospera Private Wealth LLC acquired a new stake in Novo Nordisk A/S during the third quarter valued at $357,000. Strategy Asset Managers LLC boosted its position in Novo Nordisk A/S by 102.3% during the third quarter. Strategy Asset Managers LLC now owns 4,364 shares of the company’s stock valued at $520,000 after purchasing an additional 2,207 shares during the last quarter. Commerce Bank boosted its position in Novo Nordisk A/S by 16.0% during the third quarter. Commerce Bank now owns 32,534 shares of the company’s stock valued at $3,874,000 after purchasing an additional 4,489 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its position in Novo Nordisk A/S by 55.5% during the third quarter. First Horizon Advisors Inc. now owns 7,238 shares of the company’s stock valued at $862,000 after purchasing an additional 2,582 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.3 %

Novo Nordisk A/S stock opened at $78.73 on Friday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The business’s 50-day simple moving average is $83.53 and its 200-day simple moving average is $101.66. The firm has a market capitalization of $353.32 billion, a PE ratio of 23.93, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $73.80 and a 52 week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S’s payout ratio is currently 47.72%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on NVO shares. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 13th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Stifel Nicolaus cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.